Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

There is a nationwide shortage of pediatric specialists, delaying care for many patients. In some cases, children wait weeks ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

New findings from the CONFIDENCE trial show that combination therapy with finerenone and empagliflozin leads to significantly ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® ...

In the VALIANT study, EMPAVELI demonstrated a statistically significant 68% proteinuria reduction versus placebo at Week 26, which was sustained at one year. Additionally, patients treated with ...

Rory Teeters, 7, has cystic fibrosis but with ongoing care in Rapid City from pediatric pulmonologist Dr. James Wallace, she's living her best life.

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.